Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma Plc LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.14 -1.64% 8.40 8.20 8.84 8.40 8.20 8.40 229,474 16:35:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.1 -7.2 -3.4 - 21

Immupharma Share Discussion Threads

Showing 37451 to 37474 of 37475 messages
Chat Pages: 1499  1498  1497  1496  1495  1494  1493  1492  1491  1490  1489  1488  Older
DateSubjectAuthorDiscuss
09/6/2021
08:58
Sell before it goes to 0p fair value.
ken chung
08/6/2021
15:55
TP now 2p, this coy is so pointless , I not sure why it's actually listed apart from paying extremely high salaries and to dilute PI's each year.
the stinger
08/6/2021
13:44
Everyone bailing out before the big drop! All sells and it's constant.
the stinger
07/6/2021
21:09
They may well of done yes, however has it actually got this anywhere since! Well it has fallen to 8p I suppose, good achievement eh! Must be all that news flow
the stinger
07/6/2021
20:10
That isn't really true. They funded an entire P3 themselves.
sicilian_kan
07/6/2021
14:33
The company has no prospects!!, All/Any cash is spent on wages!
the stinger
07/6/2021
14:22
Actually, I think the company has better prospects without Zimmer - albeit he was very good for the company in many ways - and it is interesting to see that the share price has not fallen since his departure, indeed at the time there was a small rise.
sicilian_kan
07/6/2021
14:20
4p TP, and that's generous
the stinger
07/6/2021
14:04
This is an excellent short.
deccer1
02/6/2021
16:39
nobbygnome - I just don't understand your obsession with IMM. Especially as you aren't even a holder, methinks.
lord loads of lolly
02/6/2021
12:04
Saw the RNS this morning.....but nope still no news of any worth! Going nowhere fast....
nobbygnome
02/6/2021
12:03
>> eva I just don't understand your obsession with IMM; they are a basket case. Meanwhile you have missed a dramatic rise at SNG.....
nobbygnome
23/5/2021
11:43
I've been years invested in IMM. Feeling pretty weary with it. Promises, promises and then nothing. When will it change?
malchr831
22/5/2021
17:59
Will be nothing I'm afraid!, Where is all that promised news flow ?. I expect 4p soon, then may look at it.
the stinger
21/5/2021
14:28
Halfbutt, Building stakes - all or nothing. Sold SNG and now adding. I want 17p and then proudly show my double portfolio of IMM. Added more today - all or nothing!
eva_1989
20/5/2021
14:40
Eva darling .... great to hear from you.x
halfbutt
20/5/2021
14:28
Loads of £3100 buys coming in... Was bored to smashed £3100 few times at 8.49 Bye. Cafe is busy so can’t chat more.. Eva
eva_1989
16/5/2021
21:46
You could well be correct, every pharma has its risks especially on AIM, but at current levels maybe worth a punt or as stated 'One To Watch' then act or not on their next RNS. - GL with any investments you have Share Tip Buddy.
share tip buddy
13/5/2021
09:28
SK this (from your post and their report) is what thy should be concentrating on as the US is a 1 trick pony that unfortunately holds all the cards and those are in the regulatory hands. US is a big market but elsewhere is bigger! "Discussions for potential partnering opportunities continue"
colsmith
12/5/2021
22:36
They say the darkest hour, is the hour before the dawn!
bbluesky
12/5/2021
20:46
Thanks sk. Looking at the balance sheet and cash burn I'd say they've got 18-24 months.
wigwammer
12/5/2021
10:19
Wigwammer Point 1) agreed Point 2) I would have agreed however the progress on the other products was massively disappointing in the last update. We were expecting 2x bioequivalence studies this year, one for Bioglucogen and one for BioAMP-B. However the one for Bioglucogen did not appear in the recent results merely stating "The next step is opening up partnering discussions". And the one for BioAMP-B merely states that there is the "potential to go immediately into a bioequivalence study in humans and submission for marketing approval" and "Discussions for potential partnering opportunities continue". Point 3) if Lupuzor fails to get FDA approval to commence Phase 3 that will affect the share price which will affect the amount of money Immupharma gets under the Lanstead deal. They are already getting less than half the expected amount with the Benchmark price being 20p I think. In summary, yes there is the potentially for very high returns here, whether BioAMP-B deal or Lupuzor going into Phase 3. But this is also very high risk and the share price could easily halve overnight if the FDA news is not good.
sicilian_kan
12/5/2021
09:18
I agree. But a few points:1) will they not get data exclusivity for a number of years?2) potential value in the other products may have an npv that substantially covers the current market cap.3) current cash plus low ongoing costs means they can continue to develop without further dilution.So yes - there is a material risk that lupuzor goes no further, but a decent cushion medium term in that event. If lupuzor does go ahead, we have the prospect of a fully funded ph3 asset sitting on a market cap of circa £25m.
wigwammer
11/5/2021
09:33
Interactive Investor have added AQSE stocks to their online trading platform. I have an II account because they bought what was once the Natwest stockbroker service. This should make AQSE stocks more liquid which is good news for Incanthera and so Immupharma
ascov
Chat Pages: 1499  1498  1497  1496  1495  1494  1493  1492  1491  1490  1489  1488  Older
ADVFN Advertorial
Your Recent History
LSE
IMM
Immupharma
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210614 16:07:50